WO2005093091A3 - Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) - Google Patents

Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) Download PDF

Info

Publication number
WO2005093091A3
WO2005093091A3 PCT/EP2005/002597 EP2005002597W WO2005093091A3 WO 2005093091 A3 WO2005093091 A3 WO 2005093091A3 EP 2005002597 W EP2005002597 W EP 2005002597W WO 2005093091 A3 WO2005093091 A3 WO 2005093091A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
gpr26
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/002597
Other languages
French (fr)
Other versions
WO2005093091A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005093091A2 publication Critical patent/WO2005093091A2/en
Publication of WO2005093091A3 publication Critical patent/WO2005093091A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Abstract

The invention provides a human GPR26 which is associated with the cardiovascular diseases, infections, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR26 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/002597 2004-03-26 2005-03-11 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) WO2005093091A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007433.8 2004-03-26
EP04007433 2004-03-26

Publications (2)

Publication Number Publication Date
WO2005093091A2 WO2005093091A2 (en) 2005-10-06
WO2005093091A3 true WO2005093091A3 (en) 2006-02-09

Family

ID=34961905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002597 WO2005093091A2 (en) 2004-03-26 2005-03-11 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)

Country Status (1)

Country Link
WO (1) WO2005093091A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049059A1 (en) * 2005-10-28 2007-05-03 Takeda Cambridge Limited Gpr 26 g-protein coupled receptor
US7872101B1 (en) * 2006-12-01 2011-01-18 Schering Corporation Modulators of the orphan G protein-coupled receptors GPR78 and GPR26
ES2736045A1 (en) * 2018-06-21 2019-12-23 Univ Cadiz METHODS FOR DIAGNOSIS AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES (Machine-translation by Google Translate, not legally binding)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037679A1 (en) * 1998-01-26 1999-07-29 Millennium Pharmaceuticals, Inc. Ligand receptors and uses therefor
GB2364057A (en) * 2000-04-04 2002-01-16 Smithkline Beecham Corp G protein coupled receptor
EP1437595A1 (en) * 2002-12-23 2004-07-14 F. Hoffmann-La Roche Ag Orphan GPCR gene 115 for obesity indication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037679A1 (en) * 1998-01-26 1999-07-29 Millennium Pharmaceuticals, Inc. Ligand receptors and uses therefor
GB2364057A (en) * 2000-04-04 2002-01-16 Smithkline Beecham Corp G protein coupled receptor
EP1437595A1 (en) * 2002-12-23 2004-07-14 F. Hoffmann-La Roche Ag Orphan GPCR gene 115 for obesity indication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADAMS F ET AL: "Cloning and characterisation of GPR26, a CNS - restricted orphan GPCR differentially regulated by antipsychotics.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 960.3 URL - http://sf, XP008050813 *

Also Published As

Publication number Publication date
WO2005093091A2 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2005114209A3 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 2 (grk2)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase